Neuburgh Advisers LLC decreased its position in shares of Core Laboratories (NYSE:CLB) by 26.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,144 shares of the oil and gas company’s stock after selling 1,520 shares during the period. Neuburgh Advisers LLC’s holdings in Core Laboratories were worth $448,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CLB. DF Dent & Co. Inc. acquired a new position in Core Laboratories during the fourth quarter worth approximately $77,449,000. Massachusetts Financial Services Co. MA increased its position in Core Laboratories by 24.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 1,787,251 shares of the oil and gas company’s stock worth $193,416,000 after buying an additional 351,847 shares during the period. TimesSquare Capital Management LLC acquired a new position in Core Laboratories during the fourth quarter worth approximately $32,005,000. WCM Investment Management CA increased its position in Core Laboratories by 5.5% during the fourth quarter. WCM Investment Management CA now owns 4,793,731 shares of the oil and gas company’s stock worth $525,153,000 after buying an additional 250,830 shares during the period. Finally, Amundi Pioneer Asset Management Inc. acquired a new position in Core Laboratories during the fourth quarter worth approximately $12,836,000.
Core Laboratories opened at $129.85 on Tuesday, Marketbeat reports. The company has a market capitalization of $5.63 billion, a PE ratio of 64.93 and a beta of 1.38. The company has a current ratio of 2.11, a quick ratio of 1.76 and a debt-to-equity ratio of 1.55. Core Laboratories has a 12-month low of $86.55 and a 12-month high of $130.34.
Core Laboratories (NYSE:CLB) last released its earnings results on Wednesday, April 25th. The oil and gas company reported $0.57 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.57. Core Laboratories had a return on equity of 62.69% and a net margin of 13.24%. The business had revenue of $170.00 million for the quarter, compared to analyst estimates of $171.03 million. During the same quarter in the previous year, the company posted $0.42 earnings per share. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. equities analysts predict that Core Laboratories will post 2.71 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, May 22nd. Investors of record on Friday, April 27th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Thursday, April 26th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.69%. Core Laboratories’s dividend payout ratio (DPR) is presently 110.00%.
Several research analysts have commented on the company. ValuEngine raised Core Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, May 17th. Zacks Investment Research lowered Core Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, May 16th. Citigroup boosted their target price on Core Laboratories from $117.00 to $123.00 and gave the company a “neutral” rating in a report on Monday, April 30th. Cowen set a $98.00 target price on Core Laboratories and gave the company a “hold” rating in a report on Friday, April 13th. Finally, Credit Suisse Group assumed coverage on Core Laboratories in a report on Thursday, March 15th. They issued an “outperform” rating and a $107.94 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $115.63.
Core Laboratories Company Profile
Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.